The US Food and Drug Administration-European Medicines Agency Collaboration in Pharmacovigilance

Common Objectives and Common Challenges

Gerald J. Dal Pan, Peter R. Arlett

Research output: Contribution to journalArticle

Abstract

On 19 February 2014, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) announced the formation of a cluster on pharmacovigilance topics. The cluster is designed to complement, and not replace, other international activities in this field. It builds upon years of interactions between the two agencies. The creation of the cluster formalizes this longstanding and productive relationship and facilitates more systematic exchange of information and expertise.

Original languageEnglish (US)
Pages (from-to)13-15
Number of pages3
JournalDrug Safety
Volume38
Issue number1
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Pharmacovigilance
United States Food and Drug Administration
Medicine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Toxicology
  • Medicine(all)

Cite this

The US Food and Drug Administration-European Medicines Agency Collaboration in Pharmacovigilance : Common Objectives and Common Challenges. / Dal Pan, Gerald J.; Arlett, Peter R.

In: Drug Safety, Vol. 38, No. 1, 2015, p. 13-15.

Research output: Contribution to journalArticle

@article{6f25791931f2401797bf5af848b14ed0,
title = "The US Food and Drug Administration-European Medicines Agency Collaboration in Pharmacovigilance: Common Objectives and Common Challenges",
abstract = "On 19 February 2014, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) announced the formation of a cluster on pharmacovigilance topics. The cluster is designed to complement, and not replace, other international activities in this field. It builds upon years of interactions between the two agencies. The creation of the cluster formalizes this longstanding and productive relationship and facilitates more systematic exchange of information and expertise.",
author = "{Dal Pan}, {Gerald J.} and Arlett, {Peter R.}",
year = "2015",
doi = "10.1007/s40264-014-0259-3",
language = "English (US)",
volume = "38",
pages = "13--15",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - The US Food and Drug Administration-European Medicines Agency Collaboration in Pharmacovigilance

T2 - Common Objectives and Common Challenges

AU - Dal Pan, Gerald J.

AU - Arlett, Peter R.

PY - 2015

Y1 - 2015

N2 - On 19 February 2014, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) announced the formation of a cluster on pharmacovigilance topics. The cluster is designed to complement, and not replace, other international activities in this field. It builds upon years of interactions between the two agencies. The creation of the cluster formalizes this longstanding and productive relationship and facilitates more systematic exchange of information and expertise.

AB - On 19 February 2014, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) announced the formation of a cluster on pharmacovigilance topics. The cluster is designed to complement, and not replace, other international activities in this field. It builds upon years of interactions between the two agencies. The creation of the cluster formalizes this longstanding and productive relationship and facilitates more systematic exchange of information and expertise.

UR - http://www.scopus.com/inward/record.url?scp=84925539785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925539785&partnerID=8YFLogxK

U2 - 10.1007/s40264-014-0259-3

DO - 10.1007/s40264-014-0259-3

M3 - Article

VL - 38

SP - 13

EP - 15

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 1

ER -